| 000 | 01901 a2200541 4500 | ||
|---|---|---|---|
| 005 | 20250514232842.0 | ||
| 264 | 0 | _c20050830 | |
| 008 | 200508s 0 0 eng d | ||
| 022 | _a0014-5793 | ||
| 024 | 7 |
_a10.1016/j.febslet.2005.06.021 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aMichiue, Hiroyuki | |
| 245 | 0 | 0 |
_aUbiquitination-resistant p53 protein transduction therapy facilitates anti-cancer effect on the growth of human malignant glioma cells. _h[electronic resource] |
| 260 |
_bFEBS letters _cJul 2005 |
||
| 300 |
_a3965-9 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 |
_aAdenoviridae _xgenetics |
| 650 | 0 | 4 |
_aAntineoplastic Agents _xpharmacology |
| 650 | 0 | 4 | _aBlotting, Western |
| 650 | 0 | 4 |
_aBrain Neoplasms _xpathology |
| 650 | 0 | 4 | _aCell Line, Tumor |
| 650 | 0 | 4 | _aCell Survival |
| 650 | 0 | 4 |
_aDNA, Complementary _xmetabolism |
| 650 | 0 | 4 | _aDose-Response Relationship, Drug |
| 650 | 0 | 4 |
_aGenes, Reporter _xgenetics |
| 650 | 0 | 4 | _aGenes, p53 |
| 650 | 0 | 4 |
_aGenetic Therapy _xmethods |
| 650 | 0 | 4 |
_aGlioma _xpathology |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aIn Situ Nick-End Labeling |
| 650 | 0 | 4 | _aMutagenesis, Site-Directed |
| 650 | 0 | 4 |
_aPeptides _xchemistry |
| 650 | 0 | 4 | _aProtein Structure, Tertiary |
| 650 | 0 | 4 |
_aRecombinant Fusion Proteins _xmetabolism |
| 650 | 0 | 4 | _aTime Factors |
| 650 | 0 | 4 | _aTranscription, Genetic |
| 650 | 0 | 4 |
_aTumor Suppressor Protein p53 _xmetabolism |
| 650 | 0 | 4 |
_aUbiquitin _xchemistry |
| 700 | 1 | _aTomizawa, Kazuhito | |
| 700 | 1 | _aMatsushita, Masayuki | |
| 700 | 1 | _aTamiya, Takashi | |
| 700 | 1 | _aLu, Yun-Fei | |
| 700 | 1 | _aIchikawa, Tomotsugu | |
| 700 | 1 | _aDate, Isao | |
| 700 | 1 | _aMatsui, Hideki | |
| 773 | 0 |
_tFEBS letters _gvol. 579 _gno. 18 _gp. 3965-9 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.febslet.2005.06.021 _zAvailable from publisher's website |
| 999 |
_c15653336 _d15653336 |
||